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 25 
Abstract 26 
Clostridium difficile infection (CDI) continues to affect many patients in hospitals and communities 27 
worldwide. Modern technologies, such as whole genome sequencing, are helping to track C. difficile 28 
transmission across healthcare facilities, countries and continents.  However, comparison of CDI 29 
epidemiology between countries is challenging due to the varied approaches to sampling and 30 
diagnosis. In this Review, we describe recent advances in the understanding of C. difficile 31 
epidemiology, transmission and diagnosis and discuss the impact these developments have on 32 
clinical management of CDI. 33 
 34 
Introduction 35 
Clostridium difficile is an anaerobic spore-forming Gram-positive bacillus which is able to colonise 36 
and proliferate in the human gut, especially following changes in the indigenous colonic microbiota 37 
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after antibiotic use. The period from spore ingestion to symptom onset is typically short,1 and is 38 
ĚĞƉĞŶĚĞŶƚŽŶŵŝĐƌŽďŝŽůŽŐŝĐĂů ?ďŝŽĐŚĞŵŝĐĂůĂŶĚ ŝŵŵƵŶĞ ĨĂĐƚŽƌƐƉƌĞƐĞŶƚŝŶƚŚĞƉĂƚŝĞŶƚ ?ƐďŽǁĞů39 
(figure 1). Importantly, human ingestion of spores does not always result in symptomatic infection. 40 
The clinical outcome after spore acquisition is variable and ranges from transient colonisation of the 41 
gut and persistent asymptomatic carriage to fulminant disease.2,3 These asymptomatic carriers of C. 42 
difficile provide a potential reservoir for onward transmission, especially within a hospital 43 
population.3  44 
 45 
C. difficile is a genetically diverse species,4 including both pathogenic (toxin-producing) and non-46 
pathogenic strains (figure 1). Thus, diagnostic tests for CDI should ideally detect only strains (or their 47 
toxins) that have the potential to cause disease. Clinical infection develops when successful 48 
germination of C. difficile spores results in toxin production within the gut lumen. The actions of two 49 
protein exotoxins, TcdA (toxin A) and TcdB (toxin B), disrupt colonic epithelial cells and stimulate the 50 
release of pro-inflammatory cytokines and chemokines. This leads to an intense inflammatory 51 
response causing acute inflammation of the large intestine. The spectrum of clinical disease ranges 52 
from mild diarrhoea to toxic mega-colon (grossly dilated bowel), colonic perforation and death. 53 
Recent research suggests that both strain characteristics ĂŶĚƚŚĞŚŽƐƚ ?ƐŝŵŵƵŶĞƌĞƐƉŽŶƐĞinfluence 54 
CDI severity, recurrence risk and mortality.5-7  55 
 56 
Recently, several advances have contributed to a new understanding of CDI. Its epidemiology is now 57 
recognised to be heterogeneous in terms of incidence and strain types reflecting different stages of 58 
epidemic spread.8 Novel fingerprinting techniques, notably whole genome sequencing (WGS) and 59 
multi-locus variable-number tandem-repeat analysis (MLVA), have indicated that C. difficile can be 60 
acquired from a wide range of sources,9 possibly including undiagnosed symptomatic cases, 61 
asymptomatic carriers (including infants), animals and food. Historically, CDI diagnosis has been 62 
complicated by the wide range of commercial tests available, and the different bacterial targets 63 
detected. In this review, we summarize the key advancements in CDI epidemiology, diagnosis and 64 
understanding of transmission. 65 
 66 
C. difficile epidemiology  67 
C. difficile was first identified as a pathogen related to antibiotic-associated diarrhoea in the late 68 
1970s.10 In the last decade of the 20th Century, CDI incidence escalated,11 becoming a well-publicised 69 
cause of hospital-acquired infection in developed countries. From 2000 onwards, there was a further 70 
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rise in CDI dominated by epidemic strains with increased pathogenicity leading to high transmission 71 
rates, increased severity and greater mortality.12 72 
 73 
Today, there are on average 7 CDI cases for every 10,000 overnight patient stays in European 74 
hospitals.13 The incidence is similar in the US where C. difficile is the leading cause of hospital 75 
associated infection, with an estimated 14,000 deaths each year.14,15 Approximately 4-10% of 76 
patients are colonised with toxigenic C. difficile on admission to a healthcare facility; this proportion 77 
rises during their stay but is extremely variable between institutions, regions and countries. 16-18 The 78 
risk of acquisition is known to increase with proximity to a symptomatic case, increasing age and 79 
longer admissions.19-20  80 
 81 
In recent years, the proportion of CDI occurring in patients outside the hospital setting has increased 82 
suggesting endemicity in the wider community, not just in hospital attendees.21 Studies have shown 83 
that community-associated CDI has been shown to affect younger, healthier patients who are less 84 
likely to have been exposed to antibiotics compared with hospital -acquired cases.21-25 A large US 85 
study (15,451 CDIs) recently demonstrated 48 community cases per 100,000 population, higher than 86 
previously reported.26 In this study, a third of CDIs were community-associated and only 24.2% of 87 
cases became symptomatic during hospitalisation. This study may have over-diagnosed cases by 88 
using a highly sensitive molecular assay that fails to differentiate between C. difficile colonisation 89 
and disease. However, these data support the view that the boundaries between hospital and 90 
community CDI are becoming less distinct. . 91 
 92 
Global epidemiology 93 
First recognised in 2002, C. difficile BI/NAP1/027 clones (Box 1) have caused large epidemics across 94 
the developed world with significant morbidity and mortality.8,12 In addition to toxins A and B, this 95 
strain produces binary toxin (known as C. difficile transferase [CDT]), also produced by a number of 96 
other strains (e.g. ribotype 078, 023).27 Infection caused by these binary toxin-producing strains has 97 
been associated with increased disease severity and 30 day mortality (though it is not clear whether 98 
it is binary toxin which contributes to adverse outcome, or other, as yet unknown factors).28-30 The 99 
incidence of B1/NAP1/027 has recently fallen in some areas of Western Europe (figure 2), due to a 100 
reduction in the total incidence of CDI as well as a reduction in the proportion of cases attributed to 101 
this strain type.31-32 However, B1/NAP1/027 persists in North America and is increasing in other 102 
areas, especially Eastern Europe.13,33-35  103 
 104 
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In Australia, similar binary toxin-producing strains, such as ribotypes 244, have recently emerged, 105 
but interestingly, C. difficile BI/NAP1/027 has yet to become established.36-38 The reasons for this are 106 
unclear, but this may reflect the relative pressures of antimicrobial selection of particular strains. For 107 
example, C. difficile BI/NAP1/027 is relatively fluoroquinolone resistant and these antibiotics are 108 
infrequently prescribed in Australia.39 In Asia, non-binary toxin strains such as ribotypes 017, 018 and 109 
014 remain dominant.40 Further understanding of global CDI epidemiology is hindered by a lack of 110 
surveillance, especially in the developing world.  111 
 112 
In the UK, where CDI surveillance is mandatory, the prevalence of C. difficile BI/NAP1/027 has 113 
markedly decreased since 2007 (figure 2).31 It has not been superseded by an alternative dominant 114 
strain, but instead, a picture of increasing diversity of strains has emerged. Such heterogenei ty is 115 
well documented elsewhere; a review of 6 US centres demonstrated 98 ribotypes in 720 toxigenic 116 
isolates41 and an Australian study showed 32 ribotypes in 70 samples.42 Such observations may 117 
simply reflect the epidemiology of C. difficile prior to the emergence of successful clones. 118 
 119 
Using C. difficile typing for epidemiological investigations 120 
C. difficile strains can be differentiated by a variety of typing techniques (Box 1) which can be used to 121 
scrutinise epidemiologically linked cases. However, challenges arise when attempting to standardise 122 
these techniques between laboratories, particularly when typing methods depend on gel banding 123 
patterns (e.g. PFGE). Multi-locus sequence typing (MLST), described by both Griffiths et al and 124 
Lemee et al in 2010,43-44 is a typing strategy which overcomes these challenges by sequencing 125 
multiple housekeeping gene fragments and using an internet-accessible database to interpret 126 
results. D>^dŚĂƐƚŚĞĂĚĚŝƚŝŽŶĂůďĞŶĞĨŝƚŽĨŐƌŽƵƉŝŶŐƐƚƌĂŝŶƐŝŶƚŽ ?ĐůĂĚĞƐ ?ďĂƐĞĚŽŶĐŽŵŵŽŶŵŽůĞĐƵůĂƌ127 
lineage. A study looking at CDI outcomes based on clades demonstrated interesting differences in 128 
disease severity and mortality (25% 14 day mortality rate in clade 5 [ST11, ribotype 078] vs. 7% in 129 
clade 3 [ST 22/5, ribotype 023]).5  130 
 131 
It is important to note that, whilst there is some concordance between typing methods (as for strain 132 
BI/NAP1/027), there are also key differences that reflect the different aspects of the genome 133 
targeted by each technique. Ribotyping uses the 16S-23S intergenic spacer region in the ribosomal 134 
RNA gene complex; 45 it is the preferred C. difficile typing method in Europe and Australia and its use 135 
has recently increased in North America. MLST and ribotyping have similar discriminatory powers 136 
but different ribotypes may be seen as a single strain by MLST, and vice versa.43 For instance, 137 
ribotype 014 falls into a number of sequence types (ST-2, ST-14, ST-50 and ST-132) and ST2 includes 138 
5 
 
multiple ribotypes (ribotype 014, 020, 076, 220, 095, 006). Similar problems arise when comparing 139 
results from other typing strategies such as PFGE, REA and MLVA (Box 1), thus hindering 140 
investigations into global epidemiology.  141 
 142 
New C. difficile typing methods, such as Whole Genome Sequencing (WGS), provide a high level of 143 
discrimination between strains aiding epidemiological investigations.4,8,9 C. difficile genomic 144 
evolution is estimated to occur at a rate of 0.74-1.49,46  single nucleotide variants (SNVs) per year, 145 
and therefore near identical strains (e.g. <2 SNVs apart) in two individuals strongly imply 146 
transmission or recent exposure to a common source, strains >10 SNVs are highly likely to be 147 
distinct.9 For interpretation of strains between 3-10 SNVs, the time between potential donor and 148 
recipient samples should be considered in the context of the C. difficile evolutionary rate. WGS can 149 
also be used to assemble phylogenetic trees to investigate the common origins of clinically relevant 150 
C. difficile strains. As an example, WGS has been used to demonstrate transcontinental spread of 151 
two distinct lineages of the BI/NAP1/027 strain.8 One lineage (FQR1) originated in the north eastern 152 
US and was transmitted to South Korea and Switzerland. A second lineage (FQR2) demonstrated 153 
wider spread with multiple trans-Atlantic transmission events between the US and Europe, some of 154 
which led to well publicised CDI outbreaks in the UK and cases in Austria, Poland and the 155 
Netherlands. The spread of both strains was preceded by the acquisition of fluoroquinolone 156 
resistance, likely due to the selection pressure of high level use of this antibiotic in N orth America.8 157 
This study highlights the influence of global travel on the spread of emerging infectious organisms 158 
and suggests there is a growing need for an internationally uniform approach to C. difficile typing. 159 
 160 
CDI transmission  161 
Both host susceptibility and strain characteristics are likely to contribute to the probability of 162 
effective C. difficile transmission, and subsequent infection, when two individuals come into contact 163 
(figure 1).5,47 The host variables associated with increased CDI risk are well characterised, and include 164 
increasing age, antibiotic use and co-morbidities.47 The characteristics leading to the success of 165 
particular strains are less well understood. 166 
Host susceptibility to CDI is known to be enhanced by changes in the host intestinal microbiota, 167 
often following hospital admission and/or antibiotic exposure.48 Recent analysis of the gut 168 
microbiome using 16S ribosomal RNA sequencing demonstrates a reduction in the diversity of host 169 
bacteria and altered predominant species in patients with CDI compared to those with either 170 
asymptomatic C. difficile colonisation or healthy subjects.49 Antimicrobial-induced dysbiosis also 171 
results in loss of protective toll-like receptor (TLR) signalling, accumulation of pro-inflammatory T 172 
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helper 17 (Th17) T cells and increased epithelial permeability.50 Thus, subsequent infection with C. 173 
difficile leads to toxin-mediated epithelial injury and perpetuation of the pro-inflammatory 174 
response.51 175 
C. difficile sporulation and germination  176 
Currently, we have a limited understanding of the reasons why some C. difficile strains have led to 177 
large transatlantic epidemics (i.e. BI/NAP1/ribotype 027), whilst others remain at a local or sporadic 178 
level. Several explanations for this  ?ŚǇƉĞƌǀŝƌƵůĞŶĐĞ ? have been proposed,52-55 and it seems likely that 179 
pathogenic factors such as germination, sporulation, epithelial adherence and toxin production may 180 
influence the success of some strains.  181 
C. difficile spores are a key feature in transmission (figure 1). Once ingested, spores interact with 182 
small molecular germinants, such as bile acids,56-57 triggering a series of events committing the spore 183 
to germinate into toxin-producing bacteria. Recently, a germination-specific protease, CspC, has 184 
been shown to play an active and essential role in germination by functioning as the C. difficile bile 185 
acid germinant receptor.58 Recent data has also begun to elucidate the activity of Spo0A, the master 186 
regulator of sporulation, which controls the transition of the bacterium into the spore form. 59-60 187 
Spo0A has also been implicated in controlling toxin gene expression, 61 intestinal colonization and 188 
disease in mice.62-63 There is early evidence that SpoOA may vary between ribotypes61 but further 189 
research is required to confirm the influence this may have on transmission and clinical disease. 190 
 191 
Toxins, immunity and C. difficile disease  192 
Investigations seeking to link quantitative toxin production with C. difficile virulence have not been 193 
conclusive.64 The clinical impact of a particular C. difficile strain is related not only to its 194 
pathogenicity, but also to the host immune response to toxin. Toxins A (TcdA) and B (TcdB) stimulate 195 
the release of multiple pro-inflammatory cytokines and chemokines (e.g. interleukin (IL)- ?ɴ ?ƚƵŵŽƵƌ196 
necrosis factor alpha (TNF-ɲ ? ?/>-8, IL-12, IL-18, IL-23, macrophage inflammatory ƉƌŽƚĞŝŶ ?ɲ ?D/W- ?ɲ ? ?197 
MIP-2, leptin) from epithelial cells and mucosal immune cells.65-68 This inflammatory response is a 198 
major determinant of disease severity69-70 and has recently been shown to correlate with persistent 199 
diarrhoea and poor clinical outcome.5,71 Importantly, toxins A and B are themselves targets of 200 
immune recognition. Antibody-mediated responses to toxins have an important role in determining 201 
asymptomatic carriage and predisposition to recurrent infection.70 Symptomless carriers of toxigenic 202 
C. difficile and those with a single episode of CDI show more robust antitoxin immune responses 203 
than those with symptomatic and recurrent disease.72-73 Recently, circulating TcdA and TcdB-specific 204 
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memory B cells have been detected following CDI, strengthening the evidence for the importance of 205 
the humoral immune response against both toxins.74 206 
  207 
Hospital acquired infection  208 
Control of CDI has conventionally centred on symptomatic cases, especially during hospital 209 
outbreaks, since these are the most recognizable sources of transmission. Whilst the exact temporal 210 
relationship between antibiotic exposure, spore exposure and symptom onset is unknown in most 211 
instances, a recent study found that most infectious periods for potential donors to support 212 
transmission of C. difficile were d1 week (65%), with only 10% >8 weeks.1 Most incubation periods in 213 
recipients were d4 weeks (61%), with few >12 weeks (13%).1  214 
 215 
CDI transmission between symptomatic patients has recently been studied in Oxford, UK, using 216 
detailed epidemiological data and WGS of consecutive isolates.9 The analysis revealed that 45% of 217 
new cases were genetically distinct from all previous cases and only 13% had recent ward contact 218 
with a previous sequence matched case (ч2 SNVs).9 Many genetically ?matched cases showed no 219 
epidemiological relationship (either hospital or community-associated) which suggests alternative 220 
sources of infection.9, This study used a suboptimal diagnostic test (a toxin enzyme-immunoassay), 221 
which lacks sensitivity, and it is likely that a proportion of true CDI cases will have rem ained 222 
undiagnosed. However, these findings have been confirmed by a confirmatory UK study using a 223 
reference standard diagnostic test75 and alternative sources of C. difficile in the healthcare setting 224 
are likely, potentially including untested symptomatic patients, asymptomatic patients, 225 
environmental contamination and healthcare workers (HCWs).  226 
 227 
The contribution of asymptomatic carriers to transmission has been confirmed in a recent study 228 
from Pittsburgh, US, in which 10.4% of inpatients carried C. difficile regardless of their symptom 229 
profile.17 MLVA typing (Box 1) showed that a third of diagnosed CDI cases had been in recent contact 230 
with a symptomatic patient, whilst another third had had contact only with an asymptomatic C. 231 
difficile carrier.17 This confirms earlier work suggesting a significant role for asymptomatic patients.3 232 
Larger multi-centre studies are needed to fully appreciate the impact of asymptomatic 233 
colonisation/carriage. A recent meta-analysis of North American studies suggests that toxigenic C. 234 
difficile carriage on admission increases the risk of subsequent CDI six -fold (21.8% vs. 3.4%, p=0.03), 235 
contrary to previous understanding that carriage reduced CDI risk.22 Notably, at present we do not 236 
have a proven intervention to address such individuals, and the resource implications for global 237 
sampling and source isolating asymptomatic patients are daunting.  238 
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 239 
Another possible source of CDI transmission is health care workers (HCWs). Although asymptomatic 240 
intestinal C. difficile colonisation in HCWs is generally uncommon, other factors, such as poor hand 241 
hygiene, have been shown to play a significant role in CDI transmission. 76 Taken together, these data 242 
suggest that source isolation of symptomatic CDI patients and control of epidemic strains, although 243 
essential interventions, may no longer be sufficient to further reduce the burden of disease in 244 
settings where outbreaks are uncommon. Further investigation of alternative sources of CDI in the 245 
hospital setting is necessary, with a focus on asymptomatic and untested patients. Alternative 246 
approaches, such as controlling exposure to antibiotics and ƌĞĚƵĐŝŶŐƉĂƚŝĞŶƚ ?ƐƐƵƐĐĞƉƚŝďŝůŝƚǇƚŽ/247 
(e.g. by vaccination) may also be required. 248 
 249 
Community-associated and community-onset CDI 250 
Community-associated infections (CA-CDI) are typically defined as those with symptom onset in the 251 
community (or within 3 days of hospital admission) without a history of hospitalisation within the 252 
previous 12 weeks. Testing for CDI in the community often lacks consistency and low diagnostic 253 
suspicion can lead to missed cases; one recent Dutch study demonstrated that only 40% of 254 
community CDI cases are successfully detected.77 CA-/ƐŚŽƵůĚŶŽƚďĞĐŽŶĨƵƐĞĚǁŝƚŚ ?ĐŽŵŵƵŶŝƚǇ-255 
ŽŶƐĞƚ ?/ ?ĂƚĞƌŵĞŶĐŽŵƉĂssing both CA-CDI and community-onset healthcare facility associated 256 
CDI. A recent large US surveillance study demonstrated that over a half of their CDI cases were 257 
community-onset.26 This study estimated that two-thirds of hospital-associated cases had symptom 258 
onset in the community, split equally between nursing home residents and patients in their own 259 
homes. The majority of community-onset hospital acquired cases occur soon after discharge 260 
suggesting either hospital acquisition or possible the use of inciting antibiotics during hospi tal 261 
admissions.78-79 Approximately 25% of true CA-CDIs are hospitalised for treatment;21 thus strains are 262 
likely to circulate frequently between hospital and community settings.   263 
 264 
It has been suggested that more than half CA-CDIs have outpatient (OPD) healthcare exposure in the 265 
weeks prior to infection.  24 CA-CDI is also well recognised in residents of long term care (LTC) 266 
facilities (LTC cases are classified as healthcare associated in some countries including the US),77 with 267 
hospital strains being regularly introduced by both asymptomatic and symptomatic hospital 268 
attendees.80-81 A recent meta-analysis including 9 studies, mainly from North America, demonstrated 269 
a 14.8% rate of asymptomatic carriage of toxigenic strains in LTC residents.81 Colonisation was 270 
associated with previous CDI, prior hospitalisation and antimicrobial use. Previously, a survey in 271 
Germany demonstrated an approximate five-fold increase in C. difficile colonisation of LTC residents 272 
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compared to elderly people living in their own homes.82  Further data are needed on the significance 273 
of both OPD visits and LTC residence in CA-CDI transmission; in both instances, CDI incidence is likely 274 
to be dependent on the susceptibility of other attendees.  275 
 276 
Asymptomatic C. difficile carriage in infants is another potential reservoir for CDI. Contact with 277 
children <2 years old has previously been shown to be a risk factor for CA-CDI.83 More recently, two 278 
small studies have shown 22-45% of healthy infants to be colonised with C. difficile at a single point 279 
in time, with the majority of these infants being affected during the first year of life.  84-85 Pathogenic 280 
strains were retrieved in both studies, but ribotypes seen most frequently in adult CDI (e.g. ribotypes 281 
027/078) were not seen in healthy children. Not all studies have demonstrated the association 282 
between infants and CDI.77 283 
 284 
Finally, environmental sources may be relevant to CA-CDI. Toxigenic and non-toxigenic C. difficile 285 
strains can be recovered from the faeces of piglets, cattle, horses and poultry risking transmission to 286 
humans via direct contact, food and the environment.25,86 Recent studies in the Netherlands, where 287 
high density pig farming is present in some parts of the country, have demonstrated potential 288 
spread of C. difficile between farm animals and humans.87-88 The reported prevalence of C. difficile in 289 
 ?ŽĨĨƚŚĞƐŚĞůĨ ?ĨŽŽĚƐŝƐ generally low but extremely variable (0-42%), with ground meat, shellfish, 290 
vegetables and pre-packed salads most commonly contaminated.86-89 However, no food-related 291 
outbreaks have been reported.  292 
 293 
C. difficile has also been recovered from water, soil90 and household environs; one small US study 294 
demonstrated toxigenic C. difficile on 25/63 (39.7%) of shoe swabs.91 However, the relative 295 
importance of exposure to infants, animals and the environment has remained elusive, perhaps 296 
reflecting the fact that the majority of the population lacks vulnerability to CDI due to colonisation 297 
resistance provided by healthy bowel microbiota.  298 
 299 
In summary, it is likely that community and hospital exposure to C. difficile is frequent and the 300 
consequences following spore acquisition relate to the host microbiome, host immune function and 301 
strain virulence. Further research into CDI acquisition and transmission will be challenging due to the 302 
ubiquitous nature of this bacterium, but whole genome sequencing has the potential to accurately 303 
link environmental reservoirs to human infection in the near future. 304 
 305 
CDI diagnosis  306 
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Targets for C. difficile detection 307 
CDI research has been complicated by the wide range of diagnostic tests available  (Box 2), 308 
inconsistent use of reference standards and a lack of agreement in the clinical criteria used for 309 
sampling.92-93  C. difficile produces two closely related proteins to elicit its toxic effect: TcdA (toxin A) 310 
and TcdB (toxin B). Their corresponding genes (tcdA and tcdB) are encoded by the Pathogenicity 311 
Locus (PaLoc), a chromosomally integrated DNA sequence which is variably present among strains. 94-312 
95 Strains lacking the PaLoc are not associated with disease. However, horizontal gene transfer of the 313 
PaLoc has demonstrated the potential to convert non-toxigenic strains into toxin-producers.95 Thus, 314 
tests for C. difficile infection can detect the bacterium itself, the presence of toxin or the capability of 315 
a particular strain to produce toxin. There are two reference standard tests in current use (Box 2), 316 
one for detection of toxin producing potential (cytotoxigenc culture, CC), and the other for the 317 
detection of toxin (cell cytotoxicity assay, CTA). It is vital that new tests for CDI use the appropriate 318 
reference standard in order to create accurate sensitivity/specificity data.  319 
 320 
Different C. difficile tests have been shown to correlate variably with clinical outcome.96-98 A recent 321 
prospective observational study by Polage et al demonstrated that detection of toxin genes alone 322 
(NAAT testing) over-diagnosed clinically relevant CDI.99 Toxin was detected in only half of the NAAT 323 
positive patients; toxin negative patients had a similar symptom duration as patients without 324 
toxigenic C. difficile, whilst toxin positive patients had a significantly increased risk of CDI 325 
complications and death. This study is particularly insightful since NAAT has been adopted by many 326 
centres within the US, increasing CDI rates by 50-100% in some laboratories.99 Notably, the study 327 
also confirmed the results of a recent, large, multi-centre, prospective study, which compared 12 328 
test-reference standard combinations, including assays for all three bacteriological targets (cell wall 329 
antigen, toxin genes and toxin).100 Planche et al found that cell cytotoxicity assays (CTA) were 330 
associated with increased all-cause mortality (16.6% at 30 days). Mortality was similar in patients 331 
with NAAT positive/CTA negative (9.7%) samples and those for whom both tests were negative 332 
(8.6%) suggesting that the presence of toxin itself is more indicative of mortality risk than carriage of 333 
a strain with toxin-producing potential.100 Thus, tests detecting C. difficile toxigenic potential, rather 334 
than toxin, will be likely to over-diagnose CDI with possible wide-ranging consequences. Ironically, 335 
one such consequence is overtreatment with antibiotics leading to perpetuation of gut dysbiosis , 336 
and so risking subsequent CDI.  337 
Despite the association of CDI diagnostic test results and mortality in study populations, no such 338 
assay can be guaranteed to correlate with clinical outcome in an individual; patients with a positive 339 
toxin EIA can be asymptomatic and severe infection /death can occur in patients with negative toxin 340 
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EIA.101-104 Thus; clinical judgement is always required in conjunction with test results in order to 341 
diagnose CDI accurately.  Clinical strategies to minimise inappropriate testing are also needed to 342 
avoid the risks associated with CDI treatment in asymptomatic carriers. 343 
 344 
Two-step diagnostic algorithms. 345 
Due to the failure of single commercial tests to accurately diagnose CDI, two-step algorithms for CDI 346 
diagnosis have been recommended for several years (figure 3).105-106 Forthcoming revised European 347 
guidelines on CDI diagnosis recommend two stage testing in line with UK practice. Algorithm design 348 
requires consideration of cost, speed, sensitivity and specificity. Although the optimal diagnostic 349 
strategy is still under debate, recent data suggest that using a high sensitivity test (GDH or NAAT) to 350 
screen for C. difficile can yield a rapid result with very high negative predictive value (NPV).107-108 This 351 
approach allows swift communication of negative results to clinical teams. If the screening test is 352 
positive, a second C. difficile toxin test (Toxin EIA or CTA) provides specificity for CDI. If a two-step 353 
approach gives discordant results (e.g. a positive GDH followed by a negative toxin test) then a third 354 
test can be used to increase sensitivity, e.g. NAAT. Alternatively, it is reasonable to manage the 355 
patient as if infection is present if there is a strong clinical suspicion of CDI.  Despite recent guidelines 356 
that recommend GDH or NAAT testing followed by toxin EIA,105,107-108 only 29% of European 357 
laboratories are using such a combination of tests, with 45% still using a single test.13  358 
 359 
Sampling patients for CDI 360 
It is important that the correct clinical criteria for sampling are used to identify true cases.  A US 361 
ƐƚƵĚǇĨŽƵŶĚƚŚĂƚŽǀĞƌĂƚŚŝƌĚŽĨĐůŝŶŝĐŝĂŶƌĞƋƵĞƐƚĞĚƚĞƐƚƐĚŝĚŶŽƚŵĞĞƚƚŚĞĐƌŝƚĞƌŝĂĨŽƌ ?ƐŝŐŶŝĨŝĐĂŶƚ362 
ĚŝĂƌƌŚŽĞĂ ?ŵĞĂŶŝŶŐƚŚĂƚƚŚĞĚĞƚĞĐƚŝŽŶŽĨC. difficile in these patients would be unlikely to indicate 363 
disease.93 Equally, there are also examples of CDI patients being missed due to a failure to test them, 364 
such as a Spanish point prevalence study which tested all unformed stools, regardless of whether 365 
the clinician had requested C. difficile testing, and found two-thirds of positive samples would have 366 
been missed.109 Furthermore, a pan-European study in 482 hospitals across 20 countries found that 367 
a quarter of all patients with toxigenic C. difficile were missed due to inadequate sampling/testing 368 
strategies.13 Together, these data confirm that despite the prominence of CDI as a clinical threat, 369 
considerable challenges remain when trying to correctly recognise this infection.   370 
 371 
As mentioned previously, 4-10% of asymptomatic patients are colonised with toxigenic C. difficile on 372 
arrival to hospital. Non-infectious diarrhoea is frequent in hospital patients and clinical 373 
differentiation between infectious and non-infectious symptoms is unreliable110 making it difficult to 374 
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know who to test. In order to fully understand and manage CDI, it is important to examine the 375 
interrelationship between diagnostic tests and the wide-ranging spectrum of C. difficile carriage and 376 
disease. It is then possible to identify patients who require no intervention (i.e. carrying non-377 
toxigenic strains), those who pose an infection risk to others (i.e. carrying toxigenic strains) and 378 
symptomatic patients requiring treatment (i.e. positive for C. difficile toxin). A clear and unified 379 
global approach, separately defining infectious individuals and clinical cases, would allow improved 380 
understanding of epidemiology as well as empowering clinicians to make informed decisions on who 381 
to treat and how best to utilise infection control resources.  382 
 383 
Conclusions 384 
Novel C. difficile strains have been shown to rapidly emerge and spread across countries and 385 
continents with global health impact. The reasons for the increased transmissibility of certain strains 386 
may relate to a number of factors including antibiotic resistance, sporulation and toxin production. 387 
Improved surveillance of C. difficile, in particular use of a unifying typing strategy such as WGS, is 388 
likely to revolutionize our understanding of the epidemiology of CDI. In particular, future research 389 
will help determine the main transmission routes and sources of C. difficile in non-outbreak settings 390 
and help to identify methods to reduce CDI incidence in populations at risk . However, further 391 
reduction in CDI will be challenging as evidence suggests that asymptomatic carriage may play a 392 
significant role in transmission and, unlike in other hospital associated infections such as MRSA, 393 
effective screening and decolonization strategies are not in current clinical practice. 394 
 395 
Over recent years, choosing  ?who to sample ? and  ?how to test ? for CDI have been contentious issues 396 
for clinicians. The answers to these important questions are likely to significantly influence local CDI 397 
epidemiology, diagnosis and treatment. Unlike the ease of modern rapid identification strategies for 398 
other organisms (such as mass spectrometry), C. difficile diagnosis is complicated by the need to 399 
differentiate toxin-producing from non-toxigenic strains. Evidence now suggests that using any 400 
single test as a blunt tool for both diagnosis and assessment of transmission risk is too simplistic. 401 
Improved diagnostics for CDI are needed to identify who is truly infected with, as opposed to 402 
colonized by, C. difficile. Better (more sensitive and specific) toxin detection methods would help. 403 
Improved real time CDI case ascertainment will mean that the most appropriate treatment option(s) 404 
can be targeted at the right patients whilst onward transmission can be interrupted by identification 405 
of those carrying toxigenic strains.  406 
 407 
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Box 1. C. difficile typing methods and ribotype 027/NAP1/BI/ST1. 408 
 409 
The lack of a universally accepted typing strategy has limited the comparison of strain patterns 410 
between countries and continents delaying a comprehensive global understanding of C. difficile 411 
epidemiology. Commonly used methods for C. difficile typing include ribotyping, pulsed field gel 412 
electrophoresis (PFGE), restriction endonuclease analysis (REA), multi -locus sequence typing (MLST) 413 
and multi-locus variable-number tandem-repeat analysis (MLVA).111 Each technique is reported with 414 
its own nomenclature, thus ribotype 027 is also known as NAP1 (PFGE), BI (REA) and ST1 (MLST). The 415 
various typing methods have different relative discriminatory powers; REA and MLVA show greater 416 
discrimination than ribotyping or MLST, which in turn provide greater power to separate strains than 417 
PFGE. 418 
 419 
More recently, Whole Genome Sequencing (WGS) has been used as a highly discriminatory 420 
technique allowing phylogenetic analysis of C. difficile strains to establish genetic relatedness and 421 
historical lineages.4,8-9 WGS is similar in power to MLVA, but can also demonstrate the presence of 422 
specific genes and mutations.112 High throughput technologies will soon allow WGS to be applied to 423 
clinical situations within realistic time and cost constraints.113 Current limitations of WGS include the 424 
high acquisition cost of sequencing platforms, the complexity of sequence analysis and the need to 425 
improve nomenclature for use in routine practice; thus, a consistent global approach is required. 8,114 426 
Other technologies, such mass spectrometry (e.g. Maldi -TOF), provide the potential for rapid 427 
C.difficile typing but currently lack discriminatory power compared to routine methods.115  428 
  429 
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Box 2 CDI diagnostic tests. 430 
 431 
Reference standards 432 
The two reference tests for C. difficile have different bacterial targets. Cytotoxigenic culture (CC) 433 
demonstrates the presence of C. difficile isolates with the ability to produce toxin when cultured, 434 
whereas cell cytotoxicity assay (CTA) detects the presence of toxin in stool (toxin B). Thus, CC 435 
demonstrates the presence of a toxigenic strain of C. difficile, which is important for infection 436 
control purposes but does not necessarily imply infection, whilst CTA is more closely related to 437 
disease but may miss individuals with the potential to transmit toxigenic strains to others. CTA yields 438 
fewer positive tests than CC by ignoring toxigenic strains not currently producing toxin in the patient. 439 
CTA positivity has been shown to correlate more closely with clinical outcome and mortality. 100  440 
 441 
Toxin enzyme immunoassays (EIAs)  442 
EIAs directly detect C. difficile toxin (A/B) in stool samples. EIAs are rapid, simple to use and 443 
inexpensive, which has led to their widespread use. However, they have poor diagnostic accuracy for 444 
CDI as single tests (sensitivity 60-92%).100 Thus, the use of toxin EIAs as stand-alone tests is no longer 445 
recommended.107 446 
 447 
Glutamate dehydrogenase (GDH) and nucleic acid amplification tests (NAAT)  448 
GDH testing detects a cell wall antigen (the GDH enzyme) which is produced by toxigenic and non-449 
toxigenic strains of C. difficile.120 GDH tests have high sensitivity but low specificity.100,120 A growing 450 
number of NAATs for the detection of toxin genes are now available. 121 The two methods employed 451 
are real-time polymerase chain reaction (PCR) targeting the toxin genes (tcdA/B) and loop mediated 452 
isothermal amplification (LAMP) of DNA.122-123 NAATs have high sensitivity compared with CC, but 453 
not CTA (sensitivity 87%).105,124 GDH tests and NAATs are widely used but neither detects C. difficile 454 
toxins so they cannot differentiate between asymptomatic carriage and true infection. Clinical 455 
correlation of positive results or further testing is required.  456 
 457 
